{
      "ptx_code": "PTX144",
      "chem_name": "Sorafenib",
      "casrn": "284461-73-0",
      "dtxsid": "DTXSID7041128",
      "smiles": "CNC(=O)C1=CC(OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1",
      "inchikey": "MLDQJTXFUGDVEO-UHFFFAOYSA-N",
      "label": "PTX144 | Sorafenib",
      "drugbank_id": "DB00398",
      "use_class": "Pharmaceutical",
      "tox_class": "Cardiotoxicity; Hepatotoxicity",
      "chem_name_user": "Sorafenib",
      "mw_g_mol": "464.83",
      "solubility_h2o_mol_liter": "2.11e-06",
      "source_solubility_h2o": "COMPTOX (OPERA)",
      "henry_coefficient_atm_m3_mol": "1.01e-10",
      "source_henry": "COMPTOX",
      "log_kaw_kh_rt": "8.38",
      "source_kaw": "LSER",
      "pka_acid": "",
      "pka_base": "2.17",
      "source_pka": "ACD/GALAS",
      "log_kow_liter_liter": "4.78",
      "source_kow": "mean of ACD consensus and KOWWIN",
      "log_dlipw_ph74_liter_liter": "4.95",
      "source_dlipw": "klipW (?mw = 1)",
      "freely_dissolved_fraction": "0.04",
      "density_kg_liter": "1.49",
      "source_density": "COMPTOX",
      "average_mass": "",
      "boiling_point": "",
      "source_boiling_point": "",
      "melting_point": "",
      "source_melting_point": "",
      "vapor_pressure": "",
      "source_vapor_pressure": "",
      "baseline_drerio": "2.09",
      "baseline_dmagna": "3.02",
      "baseline_celegans": "6.74",
      "baseline_xlaevis": "7.36",
      "baseline_dmelanogaster": "25.13",
      "baseline_cells": "7.83e-06",
      "baseline_cells_generic_micromole_liter_free_ec10": "2.92e-07",
      "moa_drugbank": "Sorafenib interacts with multiple intracellular (CRAF, BRAF and mutant BRAF) and cell surface kinases (KIT, FLT-3, VEGFR-2, VEGFR-3, and PDGFR-&szlig;). Several of these kinases are thought to be involved in angiogenesis, thus sorafenib reduces blood flow to the tumor. Sorafenib is unique in targeting the Raf/Mek/Erk pathway. By inhibiting these kinases, genetic transcription involving cell proliferation and angiogenesis is inhibited.",
      "protein_binding": "99.5% bound to plasma proteins.",
      "moa_t3db": "Sorafenib interacts with multiple intracellular (CRAF, BRAF and mutant BRAF) and cell surface kinases (KIT, FLT-3, VEGFR-2, VEGFR-3, and PDGFR-&szlig;). Several of these kinases are thought to be involved in angiogenesis, thus sorafenib reduces blood flow to the tumor.",
      "aop": [],
      "targets": [
            "5-hydroxytryptamine receptor 1A",
            "5-hydroxytryptamine receptor 2A",
            "5-hydroxytryptamine receptor 2B",
            "5-hydroxytryptamine receptor 2C",
            "5-hydroxytryptamine receptor 5A",
            "5-hydroxytryptamine receptor 6",
            "5-hydroxytryptamine receptor 7",
            "Fibroblast growth factor receptor 1",
            "Mast/stem cell growth factor receptor Kit",
            "Platelet-derived growth factor receptor beta",
            "Proto-oncogene tyrosine-protein kinase receptor Ret",
            "RAF proto-oncogene serine/threonine-protein kinase",
            "Receptor-type tyrosine-protein kinase FLT3",
            "Serine/threonine-protein kinase B-raf",
            "Serine/threonine-protein kinase PLK2",
            "Vascular endothelial growth factor receptor 1",
            "Vascular endothelial growth factor receptor 2",
            "Vascular endothelial growth factor receptor 3"
      ]
}